There is no clinically established, FDA-validated dose of ipamorelin for general human use. This article does not provide a personal recommendation of „how much to take daily” for bodybuilding, fat loss, or any other purpose. What it does provide is an accurate description of the doses actually used in existing controlled clinical trials, along with an honest explanation of why this dosing from a research context cannot be safely translated into a guide for self-administration.
What is the standard dose of Ipamorelin?
There is no standard, medically validated dosage of ipamorelin. It has never completed the regulatory approval process that would establish it for any indication in any country. What exists instead are specific doses used in published clinical trials, administered under direct medical supervision for particular research purposes. In a foundational human pharmacokinetic study, healthy male volunteers received ipamorelin as a 15-minute intravenous infusion. It was tested at five distinct dose levels: 4.21, 14.02, 42.13, 84.27, and 140.45 nanomoles per kilogram of body weight. The researchers measured how the growth hormone response scaled across this range [1].
In a separate Phase.
These numbers reflect what clinical researchers used, via intravenous administration, in monitored hospital or research settings. They are fundamentally different from a self-administered, at-home subcutaneous injection schedule. No study has been designed to establish an overall consumer dosage.
Since no equivalent studies exist, testing repeated self-administration for weeks or months under unmonitored conditions, this article does not translate these clinical numbers into a personal daily dosage recommendation. This is consistent with the approach taken throughout this series for CJC-1295.
Dosage of Ipamorelin for fat loss and bodybuilding
No dose of ipamorelin has been validated for fat loss or bodybuilding purposes in the peer-reviewed literature. This gap is worth taking seriously, rather than as a minor technicality. As discussed in a previous article in this series, available animal studies on ipamorelin's effect on adipose tissue actually found something surprising. It increased the weight of fat pads and food intake in mice, via a mechanism that appeared independent of growth hormone itself. This is likely related to ipamorelin's activation of the appetite-stimulating ghrelin receptor [3]. This finding directly complicates the common assumption that any dose of ipamorelin would support fat loss. No human studies have tested a specific dose for this purpose to confirm or refute this assumption in humans.
Similarly, no human studies have tested any dose of ipamorelin specifically for muscle growth or bodybuilding performance. The doses discussed above come from a pharmacokinetic study measuring hormonal response and a surgical recovery study. Neither was designed to test or measure changes in body composition over time.
Given this complete lack of outcome-based dosing data for these specific purposes, any bodybuilding or fat-loss dosing figures circulating in commercial or informal sources are not derived from clinical research. They should not be treated as validated.
How often should I take Ipamorelin?
Published studies offer real-world, albeit narrow, guidance on dosing frequency, again within a clinical rather than consumer context. A study on post-operative recovery used twice-daily intravenous dosing for a treatment period of up to seven days. This schedule was chosen to align with the short-term medical goal of that specific study – aiding post-surgical recovery. This frequency is consistent with ipamorelin's short pharmacokinetic profile. It has a half-life of approximately two hours and a single pulse of growth hormone waning within about six hours following each dose, as established in foundational pharmacokinetic studies [1], [2].
This short duration of action is part of the reason multiple, closely spaced doses were used in this clinical trial. This contrasts with a long-acting compound, such as CJC-1295 with DAC, which was tested with weekly or bi-weekly dosing due to its multi-day half-life.
It is important to state clearly that this.
Why do we not provide a practical dosing recommendation
Providing a specific dose for self-administration – in micrograms, milligrams, or injection units – would require inventing figures unsupported by validated studies. Ipamorelin has no FDA or EMA-approved dosing protocol for general use. Existing clinical doses were administered intravenously under direct medical supervision for narrow research purposes, not as a template for continuous self-subcutaneous injection.
As discussed in earlier articles in this series concerning related compounds, reviews of this broader category of peptides have specifically noted something significant. The dosing, frequency, and duration of growth hormone secretagogue use remain undetermined in the clinical literature, despite informal and commercial use having significantly increased [4].
Limitations of current evidence
The dosing numbers described in this article originate from two specific clinical trial contexts. One is a dose-escalation pharmacokinetic study. The other is a study of post-operative surgical recovery. Both used medically supervised intravenous administration. Neither was designed to establish a general dosing protocol for self-administration [1], [2].
No human studies have tested any dose of ipamorelin specifically for fat loss or muscle gain outcomes. Available animal data regarding fat metabolism actually raises questions about the fat loss assumption commonly attributed to this compound [3].
Disclaimer
Ipamorelin is not approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any equivalent regulatory body for any human use, and no standardised, medically validated dosing protocol exists for bodybuilding, fat loss, or any other purpose. It is not manufactured or sold under the quality and safety oversight that applies to approved pharmaceuticals. The dosing information in this article reflects only what has been used in controlled clinical trials, under direct medical supervision, and does not establish a safe or effective protocol for self-administration. This article is provided for general educational and informational purposes only, reflects the state of the published scientific literature at the time of writing, and does not constitute medical advice. Nothing in this article should be interpreted as a recommendation for self-administration or used to guide personal dosing decisions.
References
Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomised, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
[3] Lall, S., Tung, L. Y., Ohlsson, C., Jansson, J. O., & Dickson, S. L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and Biophysical Research Communications, 280(1), 132–138. https://doi.org/10.1006/bbrc.2000.4065
[4] Mayfield, C. K., Bolia, I. K., Feingold, C. L., Lin, E. H., Liu, J. N., Hatch, G. F. R., Gamradt, S. C., & Weber, A. E. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 54(1), 223–229. https://doi.org/10.1177/03635465251357593